Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Case Report Volume 3 Issue 8

Physiological and Ethological Effects of Sativex, A Cannabis-based Medicine, Examined on Ants as Models

Marie-Claire Cammaerts1* and Roger Cammaerts3

1Independent Researcher,Retired from the Biology of Organisms Department, University of Brussels, Belgium
2Independent Researcher, Retired from the Natural and Agricultural Environmental Studies Department (DEMNA) of the Walloon Region, Belgium

*Corresponding Author: Marie-Claire Cammaerts,Independent Researcher, Retired from the Biology of Organisms Department, University of Brussels, Belgium.

Received: May 23, 2020; Published: July 28, 2020

×

Abstract

 Sativex is a cannabis-based medicine chiefly used for treating persons suffering from multiple sclerosis.One of the qualities expected for this drug is pain easing. Using ants as models, we found that this medicine reduces theirtactile perception (which is linked to pain perception), but also that it negatively affects their orientation ability, social relationships, cognition, learning and memory. It leads to no habituation, but to no adaptation, andtosome dependence. Sativex becomes less efficient 8 hours after weaning, its effect completely vanishing in 12 - 14 hours. The small amount of ethanol contained in Sativex only somewhat decreases pain perception and memory, and do not lead to dependence. The observation of adverse effects on ants used as a model should warn practitioners that attention should be paid to persons treated with Sativex, i.e. by monitoring their behavior, social relationships, cognition, memory, and by watching for mental and orientation impairments which may present a danger when risky activities are concerned.

Keywords: Cognition; Dependence; Memory; Multiple Sclerosis; Myrmicasabuleti;Social Relationship

×

References

  1. Cammaerts MC., et al.“Some physiological and ethological effects of nicotine; studies on the ant Myrmica sabuleti as a biological model”. International Journal of Biology 6 (2014): 64-81.
  2. Cammaerts MC and Cammaerts R. “Safety of glucosamine, examined on ants as models”. MOJ Biology and Medicine4 (2018): 132-142.
  3. Cammaerts MC and Cammaerts R. “Safety of meloxicam compared to that of diclofenac using ants as models”. Acta Scientific Pharmaceutical Sciences4 (2019): 45-58
  4. Wehner R and Walter G. “Biologie et physiologie animales”. De Boek Université, Thieme Verlag, Paris, Bruxelles (1999): 844.
  5. Søvik E and Barron AB. “Invertebrate models in addiction research”. Brain Behavior and Evolution 82 (2013): 153-165.
  6. Andre RG.,et al. “Insect Models for Biomedical Research”. In: Woodhead AD, editor. Nonmammalian Animal Models for Biomedical Research.Boca Raton, FL: CRC Press (1989).
  7. Passera L and Aron S. “Les fourmis: comportement, organisation sociale et évolution”. Les Presses Scientifiques du CNRC, Ottawa, Canada 2005): 480.
  8. Cammaerts MC and Cammaerts D. “Comparative outlook over three Myrmica species’ biotopes and foragers’ know-how”. Biologia 69 (2014): 1051-1058.
  9. Cammaerts MC and Cammaerts R. “Ants’ numerosity ability defined in nine studies”. Journal of Biology and Life Sciences1 (2020): 121-142.
  10. Russo E and Guy GW. “A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol”. Medical Hypotheses 66 (2006): 234-246.
  11. Syed YY., et al. “Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A review of its use in patients with moderate to severe spasticity due to multiple sclerosis”. Drugs 74 (2014): 563-578.
  12. Boyaji S., et al. “The role of cannabidiol (CBD) in chronic pain management: An assessment of current evidence”. Current Pain and Headache Reports 24 (2020): 4.
  13. Karschner EL., et al. “Subjective and physiological effects after controlled Sativex and oral THC administration”.Clinical and Pharmacological Therapy 3 (2011): 400-407.
  14. Collin C., et al.“Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis”. European Journal of Neurology3 (2007): 290-296.
  15. Collin C., et al. “A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis”. Neurological Research5 (2010): 451-459.
  16. Nottcut W., et al.“A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)”. Multiple Sclerosis Journal2 (2012): 219-228.
  17. González RA. “A review of the effects of baclofen and THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis”.Expert Review of Neurotherapeutics10 (2018): 785-791.
  18. Hilliard A., et al. “Evaluation of the effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: A model of multiple sclerosis”.ISRN Neurology (2012).
  19. Novotna A., et al.“A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused due to multiple sclerosis”. European Journal of Neurology 9 (2011): 1122-1131.
  20. Flachenecker P., et al. “Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice - results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity”. European Neurology 71 (2014): 271-279.
  21. Russo M., et al. “Evaluating Sativex® in neuropathic pain management: A clinical and neurophysiological assessment in multiple sclerosis”. Pain Medicine6 (2016): 1145-1154.
  22. Markova J., et al. “Sativex® as add-on therapy vs. further optimized first-line antispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomized clinical trial”. International Journal of Neuroscience2 (2019): 119-128.
  23. Blake DR., et al.“Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis”. Rheumatology 45 (2006): 50-52.
  24. Nurmikko MG., et al.“Sativex successfully treats neuropathic pain characterized by allodynia: a randomized double-blind, placebo-controlled clinical trial”. Pain 1-3 (2007): 210-220.
  25. Lichtman AH., et al. “Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain”.Journal of Pain and Symptom Management2 (2018): 179-188.e1.
  26. Russo M.et al. “Sativex in the management of multiple sclerosis-related spasticity: role of corticospinal modulation”. Neural Plasticity (2015).
  27. Wade DT., et al. “Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis”.Multiple Sclerosis 12 (2006): 639-645.
  28. Constantinescu C., et al. “Long term open label treatment with Sativex® in patients with multiple sclerosis and neuropathic pain”. European Journal of PainS1 (2006): S117c-S118.
  29. Robson P. “Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine”Expert Opinion on Drug Safety 5 (2011): 675-685.
  30. GW Pharma Ltd. “Product monograph including patient medication information on Sativex, buccal spray antispastic”.Sovereign House, Histon, Cambridge, UK (2019).
  31. Vachová M., et al. “A multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term Sativex® treatment on cognition and mood of patients with spasticity due to multiple sclerosis”. Journal of Multiple Sclerosis2 (2014): 122.
  32. Russo M., et al. “Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study”. European Review for Medical and Pharmaceutical Sciences 20 (2016): 3127-3133.
  33. Russo M., et al. “Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!”. DARU Journal of Pharmaceutical Sciences1 (2015): 25.
  34. López-Sendón Merono JL., et al.“A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease”.Journal of Neurology 263 (2016): 1390-1400.
  35. Schoedel KA., et al. “Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users”.European Neuropsychopharmacology 20 (2010) 3: S587.
  36. Scott CG., et al. “A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray”. European Journal of Clinical Pharmacology. 69 (2013): 1135-1147.
  37. McGilveray IJ. “Pharmacokinetics of cannabinoids”. Pain Research and Management 10 (2005): 15A-22A.
  38. Huestis MA. “Human cannabinoid pharmacokinetics”. Chemistry and Biodiversity8 (2007): 1770-1804.
  39. Siegel S and Castellan NJ. “Nonparametric statistics for the behavioural sciences”. McGraw-Hill Book Company, Singapore (1989): 396.
  40. Cammaerts MC., et al. “An easy and cheap software-based method to assess two-dimensional trajectories parameter”. Belgian Journal of Zoology 142 (2012): 145-151.
  41. Cammaerts MC. “Colour vision in the ant Myrmica sabuleti Meinert, 1861 (Hymenoptera : Formicidae)”. Myrmecological News 10 (2007): 41-50.
  42. Cammaerts MC., et al. “Collective operant conditioning and circadian rhythms in the ant Myrmica sabuleti (Hymenoptera, Formicidae)”. Bulletin de la Société Royale Belge d’Entomologie 147(2011): 142-154.
  43. Zar JH. “Biostatistical analysis”. Prentice Hall, NJ, USA, 4th edition (1999).
  44. McDonald JH. “Handbook of biological statistics”. Sparky House Publishing (2014), Baltimore, Maryland, USA, 3rd ed (2014).
  45. Cammaerts MC. “Physical dependence on a substance occurs when the effect of this substance rapidly decreases after withdrawal”.JSM Anatomy and Physiology 1 (2018): 1017.
  46. Cammaerts-Tricot MC. et al. “Dufour’s gland secretion of Myrmica rubra: chemical, electrophysiological and ethological studies”.Journal of Insect Physiology 22 (1976): 927-932
  47. Bossong MG., et al.“Effects of Δ9-tetrahydrocannabinol on human working memory function”. Biological Psychiatry 71 (2012): 693-699.
  48. Ramaekers JG., et al. “High-potency marijuana impairs executive function and inhibitory motor control”. Neuropsychopharmacology. 31 (2006): 2296-2303.
  49. Prashad S and Filbey FM. “Cognitive motor deficits in cannabis users”. Current Opinion in Behavioral Sciences 13 (2017): 1-7.
  50. Hartman RL and Huestis MA. “Cannabis effects on driving skills”. Clinical Chemistry3 (2013): 478-492.
×

Citation

Citation: Marie-Claire Cammaerts and Roger Cammaerts. “Physiological and Ethological Effects of Sativex, A Cannabis-based Medicine, Examined on Ants as Models". Acta Scientific Pharmaceutical Sciences 4.8 (2020): 63-84.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor0.759

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US